Microbiome Science at the Kidney–Vascular Interface: Why Translation to Diagnostics and Therapies Still Lags Behind

The microbiome is a recognized modifier of immunity, metabolism, and vascular and neurological biology, with licensed therapeutics for recurrent Clostridioides difficile infection and promising applications in oncology and metabolic disease. By contrast, translation of microbiome knowledge into actionable therapies for kidney disease and hypertension remains limited. This review examines barriers to translation of microbiome effects at the kidney–vascular interface, considering mechanisms, metrics, and modifiers. Mechanistic association studies implicate microbially derived uremic toxins (indoxyl sulfate, p-cresyl sulfate, phenylacetylglutamine, trimethylamine N-oxide), short-chain fatty acids, and bile acid derivatives in kidney fibrosis, vascular and neurologic dysfunction, and blood pressure deregulation, while CKD and ensuing polypharmacy remodel oral and gut microbial communities. Candidate microbiome “metrics” – taxonomic signatures, diversity indices, and metabolite panels – lack standardization, show inconsistent replication across regions and ancestries, and provide uncertain incremental value beyond established risk markers. Interventional studies applying diets, exercise, pre-, pro-, syn- and meta-biotics, sorbents, or fecal microbiota transplantation report modest improvements in surrogate outcomes (uremic solute concentrations, inflammatory markers, blood pressure), but no convincing evidence for slower kidney function decline or fewer cardiovascular events; large controlled sorbent trials have been neutral on hard kidney endpoints. This review highlights cross-cutting obstacles, including complex confounding and reverse causation, reliance on stool-only sampling, temporal instability of microbial communities, analytic heterogeneity, strict regulation of live biotherapeutics, and inequities. Priorities to enable progress from plausible biology to clinically useful tools for CKD and hypertension include harmonized multiethnic longitudinal cohorts, multi-omic integration, and mechanism-driven intervention trials.